{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:12:26Z","timestamp":1781727146010,"version":"3.54.5"},"reference-count":55,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effect of eptinezumab on patient\u2010reported outcomes in patients with chronic migraine (CM) and medication\u2010overuse headache (MOH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MOH is a secondary headache disorder commonly occurring in patients with CM and associated with functional and psychological impairments. Medication overuse and monthly headache and migraine days were reduced with eptinezumab compared with placebo as published previously; however, these outcomes do not fully capture the burden of migraine and treatment effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PROMISE\u20102 was a phase 3, randomized, double\u2010blind, placebo\u2010controlled trial in adults with CM. Patients were randomized (1:1:1) to receive eptinezumab 100\u2009mg, eptinezumab 300\u2009mg, or placebo (up to 2 doses, 12\u2009weeks apart). Patients completed the following patient\u2010reported outcomes: 6\u2010item Headache Impact Test (HIT\u20106), Patient Global Impression of Change (PGIC), patient\u2010identified most bothersome symptom (PI\u2010MBS), and 36\u2010item Short\u2010Form Health Survey (SF\u201036).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 431 CM patients (139, 147, and 145 patients in the eptinezumab 100\u2009mg, eptinezumab 300\u2009mg, and placebo groups, respectively) had MOH diagnosed at screening (40.2% of the total PROMISE\u20102 population [\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a01072]). In CM with MOH patients, both doses of eptinezumab were associated with clinically meaningful improvements in mean HIT\u20106 total scores by week 4 and remained improved throughout the 24\u2010week study. Responder rates for individual HIT\u20106 items were greater with eptinezumab than with placebo at all time points. At week 12, almost twice as many eptinezumab\u2010treated patients indicated the PGIC was \u201cmuch\u201d or \u201cvery much\u201d improved (58.5% [79\/135, 100\u2009mg] and 67.4% [95\/147, 300\u2009mg] vs. 35.8% [48\/134, placebo]). Patients in the eptinezumab groups showed numerically greater improvements over placebo in the PI\u2010MBS and SF\u201036 scores.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This subgroup analysis in patients with CM\/MOH at baseline suggests that eptinezumab treatment is associated with early, sustained, and clinically meaningful improvements in patient\u2010reported outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14434","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T07:52:21Z","timestamp":1673509941000},"page":"264-274","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Eptinezumab improved patient\u2010reported outcomes in patients with migraine and medication\u2010overuse headache: Subgroup analysis of the randomized\n                    <scp>PROMISE<\/scp>\n                    \u20102 trial"],"prefix":"10.1111","volume":"63","author":[{"given":"Amaal J.","family":"Starling","sequence":"first","affiliation":[{"name":"Mayo Clinic  Scottsdale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Cowan","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences Stanford University Headache and Facial Pain Program  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[{"name":"Department of Neurology Albert Einstein College of Medicine  Bronx New York USA"},{"name":"Vector Psychometric Group, LLC  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Biometry and Epidemiology Medical Faculty of the University Duisburg\u2010Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Marmura","sequence":"additional","affiliation":[{"name":"Jefferson Headache Center Thomas Jefferson University Hospitals  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[{"name":"Pacific Northwest Statistical Consulting, Inc.  Woodinville WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brevig","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[{"name":"Lundbeck LLC  Deerfield Illinois USA"},{"name":"RK Consults  Ozark Missouri USA"},{"name":"Missouri State University  Springfield Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-010-0208-1"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-007-0320-4"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ajp.0000208908.50130.9b"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00546.x"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13497"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00380-8"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0946-z"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.02046.x"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-019-0796-7"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13301"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0839-1"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-019-0743-7"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-021-00982-z"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0865-z"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000001037"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.08.018"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413515338"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14056"},{"key":"e_1_2_12_25_1","first-page":"8","article-title":"Characterization of the intrinsic binding features of three antiCGRP therapeutic antibodies effective in preventing migraine: a comparative case study of ALD403, Ly2951742, TEV48125","volume":"56","author":"Latham J","year":"2016","journal-title":"Headache"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.11.007"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01186-3"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14036"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14206"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221089567"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008493"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411398400"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13946"},{"key":"e_1_2_12_39_1","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14120"},{"key":"e_1_2_12_41_1","volume-title":"The SF\u201036 Health Survey (Version 2.0) Technical Note","author":"Ware JE","year":"1996"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-200012150-00008"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200117"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00185-5"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419828994"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-009-0081-3"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1179"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000120545.45443.93"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0840-8"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00586"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1636-9"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.05.003"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007497"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007452"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14434","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14434","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:23:02Z","timestamp":1762075382000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/head.14434"],"URL":"https:\/\/doi.org\/10.1111\/head.14434","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]},"assertion":[{"value":"2022-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}